supporting your product launch

medical affairs

  • Phase 3, 3b and 4 study planning and delivery

  • RWE gathering (incl. off-label)

  • Eu TPP development

  • KOL identification and scientific engagement

  • Scientific advisory boards

  • Data presentation

  • Study authorship & publication 

  • Compliance oversight

  • Safety management

  • Medical budget planning

 marketing

  • Market sizing and asset valuation

  • Forecasting

  • European TPP development

  • Go-to-market strategy

  • Messaging & claims development

  • Branding and ID

  • Commercial advisory boards

  • Market readiness analysis

  • Launch planning

  • Marketing strategy & budget planning

market access

  • MA gap analysis

  • Pricing & pricing strategy

  • Payor identification and engagement

  • Reimbursement planning

  • Phase 3 endpoint design

  • HE&OR 

  • Economic modelling & cost-effectiveness analysis

  • Value dossier development

  • Budget impact model development

  • Market Access budget planning 

field medical

  • KOL identification and scientific engagement

  • Prescriber and payor identification and engagement

  • Reimbursement stakeholder identification and engagement

  • RWE gathering (incl. off-label)

  • Launch support

  • Medical information response

  • Compliance oversight

  • Field Medical strategy & budget planning

omni-channel

  • Customer engagement analysis

  • Operational (omnichannel build-out) planning

  • Digital compliance

  • Tactical delivery

  • Testing and implementation

  • Roll-out planning

  • Ongoing management

  • Omnichannel strategy & budget planning

Wavy Abstract Background.png

tailored to your needs

Whether you need:

  • Specific expertise (e.g. a Phase 4 Clinical Study design)

  • Whole department support (e.g. Market Access), or

  • Outsourcing of your European commercial operations

 

 LUCENT biopharma has the level of service to suit your needs.